Long-term results of cornea collagen cross-linking with riboflavin for keratoconus

Abstract

Corneal collagen cross-linking with riboflavin and UVA light (CXL) is the only method designed to arrest the progression of keratoconus. Visual improvement generally starts 3 months after treatment. Reduction is coma seen on aberrometry in early postoperative phase is also responsible for the improvement in visual acuity. In the light of currently available data we can thus say that CXL is a safe procedure that is successful in arresting keratoconus.

Keywords

• Epidemiology
• keratoconus
• prevalence
• Disease pathogenesis
• genetic heterogeneity
• genetics and genomics
• genome-wide association study
• genomic loci
• keratoconus
• linkage mapping
• molecular mechanisms
• whole exome-genome sequencing
• Deregulation
• ectasia
• gene expression
• keratoconus
• mass spectroscopy
• proteomics
• signaling pathways
• Cornea
• crosslinking
• keratoconus
• modulus
• Corneal topography
• imaging
• keratoconus
• optical coherence tomography
• placido disc based topography
• Ectatic disease
• keratoconus
• scheimpflug imaging
• Keratoconus
• ocular allergy
• vernal keratoconjunctivitis
• Contact lens
• keratoconus
• piggy back contact lenses
• rigid gas permeable
• scleral lens
• SynergEyes
• toric soft contact lens
• Corneal cross-linking techniques
• new technologies
• riboflavin
• Collagen cross linking
• Corneal collagen cross-linking
• hypoosmolar riboflavin
• keratoconus
• thin cornea
• transepithelial collagen cross-linking
• Corneal cross-linking
• radiant exposure
• ultraviolet-A
• Accelerated corneal cross linking
• keratoconus
• corneal laser surgery
• corneal ectasia
• UV light
• riboflavin
• Laser in situ keratomileusis surgery
• very high fluence collagen cross-linking
• corneal ectosia
• LASIK ectosia prophylaxis
• Cornea collagen cross linking
• keratoconus
• long term results